First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 114 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) MOST POPULAR FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer July 26, 2018 Study Links Mental Health Treatment to Improved Cancer Survival July 10, 2020 RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... April 18, 2023 EMA Recommends Granting a Marketing Authorisation for Generic Eribulin January 12, 2024 Load more HOT NEWS Study Shows Supplements Increase Risk of Relapse and Death in Breast... Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient... During No-Visitor Policy at Hospital, Surgeon Comforts Breast Cancer Patient Getting... BRCA Gene Testing: Risks, Benefits, Costs, and Coverage
